Monday 14 September

SECTION27 publishes the “SECTION27 REVIEW, April 2010 – December 2011”

“ … a great deal has been accomplished. But a great deal remains to be done … this journey has only just begun. Yet millions of lives depend upon it.” — From the forward by Vuyiseka Dubula, Chairperson of the SECTION27 Board of Directors

SECTION27 is pleased to announce the publication of the “SECTION27 REVIEW”.

The “SECTION27 REVIEW” is available by clicking “Read more” below, or by contacting Tummy Seboko (by email at seboko@section27.org.za or by phone at 011 356 4100).

The “SECTION27 REVIEW” reports on the work of SECTION27 from April 2010 to December 2011 and also assesses important aspects of the government’s compliance with its duties under section 27 of the South African Constitution. It features an introduction by the Executive Director, Mark Heywood, an organisational report, and essays by Mark Heywood, Adila Hassim and Jonathan Berger.

SECTION27 to host regional activist dialogue on Right to Health

SECTION27 to host groundbreaking Southern African Regional Activist Dialogue on Strengthening Campaigns for the Right to Health and why we need a UN Framework Convention on the Right to Health.

This year a million people will die of HIV in Eastern and Southern Africa. Hundreds of thousands more will die of easily preventable diseases. Infant and maternal mortality remains intolerably high across the region. This situation demands an enhanced and urgent response to health, yet health systems are under enormous strain, many governments are lukewarm in their response to health and international donor assistance is flagging or going into reverse, particularly the commitment to fund universal access to HIV treatment.

SECTION27, TAC and MSF South Africa call on the EU and India to stop the threats to people’s lives

The Treatment Action Campaign (TAC), SECTION27 and Médecins Sans Frontières / Doctors Without Borders (MSF) South Africa voice support for their partners across the world opposing provisions in a proposed free trade agreement (FTA) between India and the European Union (EU) that threaten the sustainable supply of affordable medicines to millions of people in the developing world.

SECTION27 and TAC applaud successful ARV medicine tender

SECTION27 and TAC applauds the successful ARV medicine tender – but call for continued actions to drive prices of essential medicines down further.

SECTION27 and TAC applaud the Minister of Health and his team at the Department of Health (DoH) for their part in conceptualising, implementing and concluding a successful antiretroviral (ARV) medicine tender. Announced yesterday, the 2010 tender – for the period 1 January 2011 to 31 December 2012 – will see the state procuring ARV medicines at or about the best prices available globally.

Health Department allows patients to get three months of antiretroviral treatment

The Department of Health has given the go-ahead for patients on antiretroviral treatment (ART) to be given three months supply of medicines instead of one month. The TAC and SECTION27 welcome this decision. It will be more convenient for patients because they will have to make fewer trips to their health facility. It will also reduce patient-load on the health system, particularly on health facility pharmacies given the shortage of pharmacists in the public health system. In a memorandum dated 2 July 2010, the Department of Health states, “There is no indication of any legislation prohibiting the supply of medicines for three months to any one patient. This practice should only be implemented once the patient has proved stable on the regimen.”

Concerns regarding Indian trade negotiations with EU

Letter to the High Commissioner for India to South Africa: Our concerns regarding Indian trade negotiations with EU.
This letter explains that the prospect of making new ARVs available in South Africa at affordable prices is under threat because of events unfolding in India. In particular, pressure is being applied by the European Union on the Indian government to sign a bilateral trade agreement that will stifle competition on essential medicines still under patent.

WDA